Alvotech (NASDAQ:ALVO) vs. Finch Therapeutics Group (NASDAQ:FNCH) Financial Survey

Finch Therapeutics Group (NASDAQ:FNCH) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Earnings & Valuation

This table compares Finch Therapeutics Group and Alvotech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	$110,000.00	161.00	-$74.75 million	($8.82)	-1.25
Alvotech	$391.87 million	10.08	-$551.73 million	($1.85)	-7.08

Finch Therapeutics Group has higher earnings, but lower revenue than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

21.8% of Finch Therapeutics Group shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 0.5% of Alvotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Finch Therapeutics Group and Alvotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0	0	0	0	0.00
Alvotech	0	0	1	0	3.00

Alvotech has a consensus target price of $18.00, indicating a potential upside of 37.40%. Given Alvotech’s stronger consensus rating and higher probable upside, analysts clearly believe Alvotech is more favorable than Finch Therapeutics Group.

Profitability

This table compares Finch Therapeutics Group and Alvotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Alvotech	-123.47%	N/A	-35.87%

Volatility & Risk

Finch Therapeutics Group has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500.

Summary

Finch Therapeutics Group beats Alvotech on 8 of the 14 factors compared between the two stocks.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.